Macquarie raises WeRide stock price target on robotaxi growth

WeRide posted first-quarter sales up 57% year over year to Rmb114 million, with revenue over the last 12 months up nearly 90% to $97.9 million and gross margin steady at about 35%. Macquarie lifted its price target to $15.90 from $15.30 and BofA to $11.80, while HSBC initiated coverage at $11.40, reflecting improving outlook for robotaxi fleet growth and international expansion. Offsetting the growth, the non-GAAP net loss widened 11% to Rmb326 million and analysts still do not expect profitability this year.

Analysis

The market is increasingly rewarding WeRide for proving that autonomy is moving from a pure R&D story into an operating leverage story, but the key second-order effect is that the company is still being valued more like an option on fleet monetization than a business with clean earnings visibility. The meaningful signal is not headline growth; it’s the combination of stable gross margin and rising utilization, which suggests incremental trips are falling through with little dilution in unit economics. That said, the widening loss despite better mix implies overhead and commercialization costs are still outrunning scale, so upside in the stock will likely depend on whether management can convert pilot expansion into sustained utilization in overseas markets rather than simply adding vehicles.

The competitive read-through is more important than the company-specific one: if WeRide can maintain near-breakeven economics in select geographies, it raises the bar for all autonomous vehicle platforms that rely on subsidy, mapping, or heavy human intervention. The Lenovo partnership matters because it potentially broadens distribution and lowers go-to-market friction, but the real economic benefit is that it may compress customer acquisition costs and accelerate OEM-style channel adoption. That would hurt smaller autonomy vendors that lack hardware and enterprise distribution leverage, and it could also pull forward demand for edge AI compute, sensors, and fleet-management software more than for the vehicles themselves.

The main risk is timing. Domestic licensing delays can be ignored for a quarter or two, but if approvals remain suspended for multiple cycles, the market will re-rate the story from “temporary policy pause” to “structural regulatory ceiling.” A second risk is geopolitics: if Middle East recovery is slower than expected, the overseas growth narrative can break quickly because the stock is likely pricing a smooth ramp in 2026, not a lumpy one. The contrarian angle is that consensus may be overestimating how quickly revenue converts into profits; for now, this is still a capital-intensive commercialization race, and the first real catalyst for a sustained rerating would be evidence of utilization improving faster than fleet expansion.

Key Decisions for Investors

• Long WRD on weakness over the next 2-4 weeks with a 6-9 month horizon; the setup is attractive if the market treats overseas expansion as an execution wedge rather than a binary regulatory bet. Use a partial position because the downside remains meaningful if licensing or Middle East execution slips.
• Buy WRD Jan-2026 call spreads rather than common stock to express upside from a 2026 commercialization re-rate while capping downside if losses stay wide; this is the cleaner way to participate in a narrative-driven name with limited profitability visibility.
• Pair trade: long WRD / short a basket of higher-multiple autonomous/robotaxi names without clear fleet monetization, sized for 3-6 months. The relative trade works if investors continue to differentiate on utilization and gross margin durability rather than headline TAM.
• Avoid chasing the stock after sharp upside days; add only on pullbacks or after evidence that overseas revenue is re-accelerating. The risk/reward improves materially if utilization moves above current levels before the next guide, not if the stock simply rerates on analyst optimism.
• If you want a lower-volatility expression of the same theme, buy suppliers exposed to autonomy deployment and AI edge compute rather than the platform equity itself; the second-order beneficiaries may capture the commercialization cycle with less execution risk.